Clinical trials · Philadelphia, PA
Metastatic Prostate Adenocarcinoma clinical trials in Philadelphia
We’re tracking 34 recruiting metastatic prostate adenocarcinoma studies with a site in or near Philadelphia — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT03972657RecruitingPhase 1/Phase 2
Testing a new prostate and kidney cancer drug with immunotherapy
This early trial tests whether REGN5678 (nezastomig) is safe and how well it works, either by itself or with an immunotherapy drug (cemiplimab). It targets adults with metastatic castration-resistant prostate cancer and certain metastatic kidney cancers that have already been treated.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Philadelphia, PennsylvaniaAges 18–100 - NCT04221542RecruitingPhase 1
AMG 509 for advanced, hormone-resistant prostate cancer
This trial tests AMG 509, a study drug, in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite lowering testosterone). It’s for people whose cancer has progressed after certain hormone tablets and possibly chemotherapy, aiming to shrink tumors and control the disease safely.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07028853RecruitingPhase 3
New drug combo for advanced prostate cancer
This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT04729114RecruitingPhase 1
Safety and dose test of PRL-02 shot for advanced prostate cancer
This Phase 1 study tests how safe PRL-02 depot (an injection) is and finds the best dose for men with advanced prostate cancer. It may help determine a new treatment option for cancers that have spread or are getting worse despite standard care.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT07225946RecruitingPhase 3
Study of pasritamig with docetaxel for advanced prostate cancer
This trial tests a new drug called pasritamig combined with the chemotherapy docetaxel, compared to docetaxel alone, in men with prostate cancer that has spread and is no longer responding to hormone therapy.
Bala-Cynwyd, PennsylvaniaAges 18 years+ - NCT05946213RecruitingPhase 3
Shorter radiation treatment for high-risk prostate cancer
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
Chadds Ford, PennsylvaniaAges 18 years+ - NCT07200830RecruitingPhase 3
Testing different schedules of a targeted radiation drug for advanced prostate cancer
This trial tests two different dosing schedules of a drug called Lutetium-177 PSMA RLT, which delivers radiation directly to prostate cancer cells. It is for men with advanced prostate cancer that has stopped responding to hormone therapy and has spread, who have not yet had chemotherapy for this stage of the disease.
Pennington, New JerseyAges 18 years+ - NCT07213674RecruitingPhase 3
A study of xaluritamig plus abiraterone for prostate cancer
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
Newark, DelawareAges 18 years+ - NCT03866382RecruitingPhase 2
Immunotherapy plus a targeted drug for rare genitourinary tumors
This Phase 2 study tests whether nivolumab and ipilimumab (immunotherapy drugs) plus cabozantinib (a targeted anti-cancer drug) can shrink or control rare cancers of the urinary/reproductive system that have spread. It may help by boosting the immune system and blocking cancer growth signals at the same time.
Bethlehem, PennsylvaniaAges 18 years+
Hear when a new Metastatic Prostate Adenocarcinoma trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Prostate Adenocarcinoma trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting metastatic prostate adenocarcinoma studies listed above.
- Medical Oncology Hematology Consultants PA · 3 studies
- MidLantic Urology · 3 studies
- Thomas Jefferson University Hospital · 3 studies
- Capital Health Medical Center - Hopewell · 2 studies
- Helen F Graham Cancer Center · 2 studies
- Lehigh Valley Hospital-Cedar Crest · 2 studies
- AtlantiCare Surgery Center
- Christiana Care Health System-Concord Health Center
What taking part in a metastatic prostate adenocarcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic prostate adenocarcinoma studies in Pennsylvania.
Common questions
- Are there metastatic prostate adenocarcinoma clinical trials near Philadelphia?
- Yes. We're currently tracking 34 recruiting metastatic prostate adenocarcinoma studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic prostate adenocarcinoma study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic prostate adenocarcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic prostate adenocarcinoma studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.